Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat versus allopurinol in Pakistani adults with hyperuricemia
ACTRN12612000434897Phase 4Recruiting
- Sponsor
- PharmEvo
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hyperuricemia and gout comparing Febuxostat with Allopurinol (2 arms). Primary endpoint: Urate lowering response. Started Apr 2012; status: recruiting.
02
Drugs
febuxostatallopurinol
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on ACTRN12612000434897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000434897.